Full Press Release Details
Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts
for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
SYDNEY, AUSTRALIA - 10 November 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the
Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that data from its AIPAC, TACTI-002 and TACTI-003 studies have been published in abstracts available via the links below on the SITC 2021 Annual Meeting s official website or the Company s
Three poster presentations with additional data and commentary that are not included in the abstracts will be available on
https://www.sitcancer.org/2021/home from 12 November 2021, at 7 am EST and made available on Immutep s website at www.immutep.com.
| TACTI-002 | ||
| Title: | Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC). | |
| Abstract: | https://www.immutep.com/files/content/investor/presentation/2021/SITC/TACTI-002_Abstract_SITC%202021_final.pdf | |
| TACTI-003 | ||
| Title: | A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC). | |
| Abstract: | https://www.immutep.com/files/content/investor/presentation/2021/SITC/TACTI-003_Abstract_SITC%202021_final.pdf | |
| AIPAC | ||
| Note: | A separate announcement detailing the AIPAC results has also been released today. |
Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000
| Title: | Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC. | |
| Abstract: | https://www.immutep.com/files/content/investor/presentation/2021/SITC/AIPAC_ Abstract_SITC%202021_final.pdf | |
| Webcast Details | ||
| Immutep will present the AIPAC data in a global webcast for investors. Details are as follows: | ||
| Date & Time: | 8.00 am AEDT (Sydney) Wednesday 17 November 2021 | |
| 4.00 pm EST (New York) Tuesday 16 November 2021 | ||
| 10.00 pm CET (Berlin) Tuesday 16 November 2021 | ||
| Register: | https://fnn.webex.com/fnn/onstage/g.php?MTID=ef12af93633b5d17a2e4e176fcac2f070 | |
| Questions: | Investors are invited to submit questions in advance via immutep@citadelmagnus.com . |
a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging
its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
lead product candidate is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3 protein, which is a
first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Additional LAG-3 products, including
antibodies for immune response modulation, are being developed by Immutep s large pharmaceutical partners.
Immutep is listed on the Australian
Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Further information can be found on the Company s website
www.immutep.com or by contacting:
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
This announcement was authorised for release by the Board of Immutep Limited.
Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000